MX352315B - Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas. - Google Patents

Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.

Info

Publication number
MX352315B
MX352315B MX2014005532A MX2014005532A MX352315B MX 352315 B MX352315 B MX 352315B MX 2014005532 A MX2014005532 A MX 2014005532A MX 2014005532 A MX2014005532 A MX 2014005532A MX 352315 B MX352315 B MX 352315B
Authority
MX
Mexico
Prior art keywords
pain
fatigue
formulations
treatment
wounds
Prior art date
Application number
MX2014005532A
Other languages
English (en)
Inventor
L Hsia Sung
R Narain Niven
Persaud Indushekhar
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Publication of MX352315B publication Critical patent/MX352315B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a CoQ10 tiene un efecto estimulante sobre los fibroblastos y queratinocitos, incrementa producción de ATP, disminuye el dolor. Las formulaciones son útiles para promover curación de heridas agudas, fatiga y tratamiento de dolor agudo y crónico.
MX2014005532A 2006-05-02 2007-05-02 Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas. MX352315B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79700806P 2006-05-02 2006-05-02
PCT/US2007/068052 WO2007131047A2 (en) 2006-05-02 2007-05-02 Topical co-enzyme q10 formulations and treatment of pain, fatigue and wounds

Publications (1)

Publication Number Publication Date
MX352315B true MX352315B (es) 2017-11-17

Family

ID=38668517

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014005532A MX352315B (es) 2006-05-02 2007-05-02 Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
MX2008013855A MX2008013855A (es) 2006-05-02 2007-05-02 Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2008013855A MX2008013855A (es) 2006-05-02 2007-05-02 Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.

Country Status (7)

Country Link
US (2) US10583098B2 (es)
EP (2) EP3173068B1 (es)
JP (2) JP2009536215A (es)
CA (3) CA2894933C (es)
ES (2) ES2836184T3 (es)
MX (2) MX352315B (es)
WO (1) WO2007131047A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073843A1 (en) * 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
CA2761717A1 (en) * 2009-05-11 2010-11-18 Berg Biosystems, Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
CN102892412B (zh) 2010-03-12 2015-09-30 博格制药有限责任公司 辅酶Q10(CoQ10)的静脉内制剂及其使用方法
AU2012240222B2 (en) * 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
US10973763B2 (en) 2011-06-17 2021-04-13 Berg Llc Inhalable pharmaceutical compositions
MX2015014097A (es) 2013-04-08 2016-06-07 Berg Llc Tratamiento de cancer empleando terapias combinadas de coenzima q10.
EP2997084A4 (en) 2013-05-17 2016-10-12 Acupac Packaging Inc ANHYDROUS HYDROGEL COMPOSITION
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
US20160081959A1 (en) * 2014-09-24 2016-03-24 Glanbia Plc Method of using arginine silicate inositol complex for wound healing or repair
US10130669B2 (en) * 2014-12-29 2018-11-20 Ronald K. Gilbert Method and system for treating wounds
KR101905010B1 (ko) * 2016-04-19 2018-10-08 앱티스 주식회사 코엔자임 q10 가용화 조성물 및 이의 제조방법
MA52274A (fr) * 2017-05-17 2021-02-24 Berg Llc Utilisation de formulations de coenzyme q10 dans le traitement et la prévention de l'épidermolyse bulleuse
US20230050858A1 (en) * 2021-08-03 2023-02-16 Desert Harvest, Inc. Methods and compounds for natural organic intensive skin repair and healing

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS588010A (ja) * 1981-07-08 1983-01-18 Eisai Co Ltd ユビデカレノン含有リポソ−ム
JPS58201711A (ja) 1982-05-19 1983-11-24 Eisai Co Ltd ユビデカレノン含有リポソ−ム被覆体
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JPS6277318A (ja) * 1985-10-01 1987-04-09 Eisai Co Ltd 熱傷治療剤
JPS6339813A (ja) 1986-08-05 1988-02-20 Eisai Co Ltd 創傷治療剤
US6764693B1 (en) * 1992-12-11 2004-07-20 Amaox, Ltd. Free radical quenching composition and a method to increase intracellular and/or extracellular antioxidants
US5863556A (en) * 1993-08-20 1999-01-26 Euro-Celtique, S.A. Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
BR9509590A (pt) * 1994-11-04 1997-12-23 Polymun Scient Immunbio Forsch Aplicação de sod em liposomas
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5891469A (en) 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
EP1009383A1 (en) * 1997-09-04 2000-06-21 Biozone Laboratories, Inc. Oral liposomal delivery system
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US20050019268A1 (en) 1999-02-11 2005-01-27 Mse Pharmazeutika Gmbh Spray containing ubiquinone Qn
DE19905879A1 (de) * 1999-02-11 2000-08-17 Mse Pharmazeutika Gmbh Ubichinon Qn zur Behandlung von Schmerzen
US20040034107A1 (en) * 1999-02-11 2004-02-19 Mse Pharmazeutika Gmbh Ubiquinone Qn for the treatment of pain
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20020048551A1 (en) * 1999-04-06 2002-04-25 Keller Brian C. Delivery of biologically active material in a liposomal formulation for administration into the mouth
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
IT1307281B1 (it) * 1999-11-25 2001-10-30 Simonelli Giuseppe Uso di ubichinone q10 per il trattamento locale e la prevenzione dipatalogie oftalmologiche secondarie alla terapia fotorefrattiva,
GB2360706B (en) * 2000-02-09 2002-07-17 Paul A Sneed Treatment of fibromyalgia with ubiquinone 10 and succinic acid
WO2001082899A2 (en) * 2000-05-03 2001-11-08 Mbt Munich Biotechnology Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
ATE402692T1 (de) * 2000-05-09 2008-08-15 Kaneka Corp Dermale zusammenstellungen die als wirkstoff coenzym q enthalten
US6465517B1 (en) 2000-07-11 2002-10-15 N.V. Nutricia Composition for the treatment of migraine
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
AUPR177300A0 (en) * 2000-11-29 2000-12-21 Centre For Molecular Biology And Medicine Therapeutic methods
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
AU2002309038B2 (en) 2001-05-10 2007-05-17 Kaneka Corporation Compositions for transmucosal administration containing coenzyme Q as the active ingredient
CN1268328C (zh) 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
US20030105027A1 (en) 2001-11-06 2003-06-05 Rosenbloom Richard A. Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
US7435725B2 (en) 2001-11-06 2008-10-14 The Quigly Corporation Oral compositions and methods for prevention, reduction and treatment of radiation injury
US6753325B2 (en) 2001-11-06 2004-06-22 The Quigley Corporation Composition and method for prevention, reduction and treatment of radiation dermatitis
US20030105031A1 (en) * 2001-11-06 2003-06-05 Rosenbloom Richard A. Methods for the treatment of skin disorders
US20030118536A1 (en) 2001-11-06 2003-06-26 Rosenbloom Richard A. Topical compositions and methods for treatment of adverse effects of ionizing radiation
US9034310B2 (en) * 2002-02-21 2015-05-19 Stephen B. Cantrell Interferon-statin combination cancer therapy
WO2003075900A2 (de) * 2002-03-09 2003-09-18 Mse Pharmazeutika Gmbh Verwendung von ubichinonen zur beeinflussung der histaminwirkung zur behandlung von bronchitis, asthma, allergischen krankheiten
US7060733B2 (en) 2002-08-15 2006-06-13 The Regents Of The University Of California Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
TWI322008B (en) * 2003-01-31 2010-03-21 Kaneka Corp Fatigue improving agent including reduced coenzyme q10
CN1208052C (zh) * 2003-03-20 2005-06-29 上海家化联合股份有限公司 一种辅酶q10前体脂质体及其制备方法
US8252322B2 (en) * 2003-06-03 2012-08-28 Corn Products Development, Inc. Delivery system with increased bioavailability
RU2006101991A (ru) 2003-06-25 2006-06-27 Чарлз ЭРВИН (US) Химическая композиция и способ увеличения подачи кофермента q10
US7169385B2 (en) 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US20070009583A1 (en) * 2003-10-10 2007-01-11 Qvist Michael H Dressing
ME01881B (me) 2004-01-22 2014-12-20 Univ Miami Topijske formulacije koenzima q10 i postupci upotrebe
US20050208118A1 (en) * 2004-03-18 2005-09-22 Takemoto Arnold C Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals
EP1784193A4 (en) * 2004-06-28 2009-09-23 Smith Howard J & Ass Pty Ltd COMPOSITION AND METHOD FOR THE TREATMENT AND PREVENTION OF ATHEROSCLEROSIS
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
KR101947126B1 (ko) * 2010-12-28 2019-02-13 카메디스 리미티드 감염의 치료 및 예방을 위한 식물 추출물
US9211256B2 (en) * 2011-03-08 2015-12-15 The Johns Hopkins University Wound healing compositions comprising biocompatible cellulose hydrogel membranes and methods of use thereof

Also Published As

Publication number Publication date
US20210000761A1 (en) 2021-01-07
CA2650825A1 (en) 2007-11-15
ES2620389T3 (es) 2017-06-28
WO2007131047A2 (en) 2007-11-15
EP2073819A2 (en) 2009-07-01
EP3173068A1 (en) 2017-05-31
WO2007131047A3 (en) 2008-07-24
EP3173068B1 (en) 2020-09-09
JP5968865B2 (ja) 2016-08-10
EP2073819B1 (en) 2016-12-28
CA2894933A1 (en) 2007-11-15
CA2977089A1 (en) 2007-11-15
US10583098B2 (en) 2020-03-10
US20100062048A1 (en) 2010-03-11
JP2014058559A (ja) 2014-04-03
EP2073819A4 (en) 2013-02-20
CA2650825C (en) 2015-07-14
ES2836184T3 (es) 2021-06-24
MX2008013855A (es) 2009-01-29
JP2009536215A (ja) 2009-10-08
CA2894933C (en) 2017-10-03

Similar Documents

Publication Publication Date Title
MX352315B (es) Formulaciones de co-enzima topica q10 y tratamiento de dolor, fatiga y heridas.
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
WO2010005910A3 (en) Maggot debridement therapy dressings and methods
AU2011328009A8 (en) Compounds and methods for treating pain
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
HK1122803A1 (es)
MY167691A (en) A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
MY145769A (en) Method for treating or preventing systemic inflammation
WO2006048242A3 (en) Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
TN2010000288A1 (en) 4-(4-cyano-2-thioaryl) dihydropyrimidines and use thereof
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
IL201479A (en) Use of tapentadol for the preparation of pain medication
RS52102B (en) PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
WO2011140310A3 (en) Povidone-iodine topical composition
NZ601350A (en) Method of treating arthritis
UA102238C2 (en) 4-(4-cyano-2-thioaryl)dihydro-pyrimidinones and use thereof
MY150931A (en) Substituted oxazolidinones and their use
WO2008119097A8 (de) Pharmazeutisches mittel gegen juckreiz und schmerz
USD629114S1 (en) Set of bandages for a healing wound
BRPI0608328A2 (pt) uso de lactobacillus rhamnosus gg para tratamento, prevenção ou redução de inflamação sistêmica em um bebê alimentado com fórmula
WO2008017927A3 (en) Method for treating skin wounds
WO2009050677A3 (fr) Utilisation de bacteries lactiques pour la prevention et/ou le traitement de pathologies cutanees
EA200801678A1 (ru) Применение производных триазина для производства лекарственного средства, обладающего заживляющим или ангиогенным эффектом